LOCATION : Home - About Us

Shandong Tianming Pharmaceutical is a state-level high and new tech enterprise that is engaged in the innovation, manufacture and sales for genieric drugs. It was registered and established in 2010 with a registered capital of 40 million. The factory is located in Pingyuan County, Dezhou City, Lukang Industrial Park, Zoucheng City, Jining City, and Daren Industrial Park, Hechi, Guangxi. The R&D center is located in High-tech Zone, Jinan City, and Qixia District, Nanjing City. The fields involved in the products include antibiotic drugs, cardiovascular drugs, diabetes drugs, anti-tumor drugs, health care products, etc.

1. Overview of business management

In terms of corporate management, the company continues to increase investment in environmental protection and has passed the dual-system acceptance; invests more than 10% of its turnover in R&D and innovation every year, and drives rapid development with scientific research; implements 6S management, and the site environment is clean and tidy. The company continuously strengthens internal control construction, strengthens financial control, seeks benefits from management, improves the company's unit benefits through amoeba operation, and comprehensively improves the company's management level with IPD integrated control and comprehensive budget; Guangxi company put into production, increasing the company's output value and production capacity; the company Purchase a scientific research building in Jinan High-tech Zone and set up Jinan R&D Center; set up Nanjing R&D Center in Qixia District, Nanjing. Actively research and develop new drugs to continuously enhance the company's technological competitiveness. In 2017, it was listed on the Qilu Equity Exchange Center (equity code 301926), which further standardized the enterprise and improved the success rate of financing. In terms of sales, we will continue to increase domestic and foreign sales revenue and increase the number of exports.


2. The company’s main products
The company’s products cover antibiotic drugs (Cefometoxime, Cefazerone, Cefpirin), cardiovascular drugs (LCZ696), diabetes drugs (Alogliptin, Trelagliptin , Linagliptin) and anti-tumor drugs Medication (Ibrutinib, Barictinib, Tofacitinib), etc. The company's products are mainly exported to South Korea, India and other countries. 

The company has its own unique advantages in the development of pharmaceutical raw materials and intermediate production processes. The preparation method provided by the authorized invention patent "a preparation method of Trelagliptin " has mild reaction conditions, high conversion rate, less impurities, low cost, and high purity of the finished product, which is more suitable for industrial production. The invention patent "a method for preparing cefmenoxime hydrochloride" has cheap and easy raw materials, high product purity and high yield, which is beneficial to the realization of industrial production.


3. Basic situation of enterprise innovation

The company's research and development level of antibiotic drugs and diabetes drugs ranks among the most advanced in China. It has a research and development team of more than 100 people, of which more than 70% are master and doctoral students, and hired Professor Hou Zhaosheng from Shandong Normal University as a technical consultant. Experts with R&D experience guide the technology R&D and production in detail. In October 2018, Dezhou Company was awarded the title of "Specialized, Specialized and New" SME in Shandong Province, in November 2018, passed the "National High-tech Enterprise", in December 2018, passed the "Dezhou Anti-diabetic Drug Engineering Technology Research Center", in April 2019, passed the Received the honor of "Technology-based Small and Medium-sized Enterprises" in Shandong Province in June, passed the "Key Laboratory of Anti-diabetic Drugs" in Dezhou in June 2020, was recognized as the "Enterprise Technology Center" in Dezhou in December 2021, and was approved in March 2023 It is the "Shandong Postdoctoral Innovation Practice Base", and in June 2023, it was recognized as the "One Enterprise, One Technology R&D Center" in Shandong Province.
In March 2022, Jinan Company won the honor of "Technology-based Small and Medium-sized Enterprises" in Shandong Province, in January 2023 passed the "National High-tech Enterprise", in April 2023 won the title of "Innovative Small and Medium-sized Enterprises" in Shandong Province, and in May 2023 won the honor of Shandong Province The honor of "specialized, special and new small and medium-sized enterprises" in the province.
In 2021, Nanjing Company was rated as a "Technology-based Small and Medium-sized Enterprise" in Jiangsu Province.
In May 2023, Guangxi Company won the honor of "Technology-based Small and Medium-sized Enterprises" in Guangxi Zhuang Autonomous Region.


4. Basic situation of enterprise system constructionThe company has passed the ISO9001 quality system certification, with a credit rating of 3A. It has obtained the evaluation certificate of the integration of industrialization and industrialization management system, and was rated as an "excellent enterprise for the integration of industrialization and industrialization" in Shandong Province. Implemented "6S on-site management" and amoeba business accounting for departmental accounting. And passed the safe double system acceptance and implementation.